regulatory
confidence high
sentiment positive
materiality 0.70
PepGen receives FDA orphan drug and rare pediatric disease designations for DMD candidate PGN-EDO51
PepGen Inc.
- FDA granted orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapy for DMD.
- PGN-EDO51 targets DMD patients whose mutations are amenable to exon 51 skipping approach.
- Ongoing CONNECT1 Phase 2 trial; CONNECT2 Phase 2 enrollment expected later in 2024.
- Orphan designation offers 7-year U.S. exclusivity plus tax credits and fee benefits upon approval.
- Rare pediatric disease designation may yield a priority review voucher for a future product.